News in Numbers

In March 2026, Blackstone closed a funding raise that has brought in $6.3bn in capital to support its ongoing life sciences investment strategy – marking the largest life sciences private fund ever raised. 

UCB is set to invest $2bn in a new biologics manufacturing facility in Georgia, US. 

The head and neck squamous cell carcinoma (HNSCC) therapeutics market is set to reach a valuation of $4.5bn across the eight major markets in 2034, as per GlobalData analysis. 

A report by the London Assembly’s health committee has found that just 3,000 London residents are accessing weight loss medicines on the NHS, with the majority doing so privately. 

The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets is projected to reach a valuation of $5.9bn in 2034, as per GlobalData analysis.